Trevi Therapeutics (TRVI) Capital Leases (2023)
Trevi Therapeutics' quarterly Capital Leases came in at $31000.0 in Q4 2023, down 50.0% quarter-over-quarter from $62000.0 in Q3 2023.
Trevi Therapeutics has reported Capital Leases for 1 years, with the latest figure at $31000.0 in Q4 2023.
- For the quarter ending Q4 2023, Capital Leases changed N/A year-over-year to $31000.0; the trailing twelve-month figure through Dec 2023 stood at $31000.0 (changed N/A YoY), and the FY2023 full-year result was $31000.0, changed N/A from the prior year.
- Capital Leases for Q4 2023 stood at $31000.0, down from $62000.0 in the prior quarter.
- The five-year high for Capital Leases was $124000.0 in Q1 2023, with the low at $31000.0 in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 31,000.00 |
| Sep 30, 2023 | 62,000.00 |
| Jun 30, 2023 | 93,000.00 |
| Mar 31, 2023 | 124,000.00 |